ベルビシンの新興薬剤に関する洞察と市場予測：2032年

ベルビシンはアントラサイクリン系抗がん剤の一種で、最も強力な化学療法薬のひとつであり、他のどの化学療法薬よりも多くの種類のがんに有効です。アントラサイクリン系抗がん剤は、自然のプロセスを利用して、細胞増殖を可能にする重要な酵素であるトポイソメラーゼIIの働きを阻害することにより、標的とするがん細胞にデオキシリボ核酸（DNA）損傷を誘発します。脳腫瘍患者に対するベルビシンの治療は、Reata Pharmaceuticals社が実施した第I相臨床試験において、1例の持続的完全奏効を含む良好な奏効を示しました。ベルビシンは現在、極めて重要な可能性を秘めた国際共同試験で評価されています。

今後数年間で、多形性膠芽腫（GBM）の市場シナリオは、世界中の広範な研究と医療支出の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、ベルビシンの優位性に影響を与える可能性のある機会を模索しています。GBMに対する他の新興製品は、ベルビシンに厳しい市場競争をもたらすと予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるベルビシン市場について調査し、市場の概要とともに、2025年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 多形性膠芽腫（GBM）に対するベルビシンの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 ベルビシン市場評価

• GBMに対するベルビシンの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるGBMに対するベルビシンの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Berubicin, Clinical Trial Description, 2023
• Table 2: Berubicin, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Berubicin Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Berubicin Market Size in the US, in USD million (2019-2032)
• Table 7: Berubicin Market Size in Germany, in USD million (2019-2032)
• Table 8: Berubicin Market Size in France, in USD million (2019-2032)
• Table 9: Berubicin Market Size in Italy, in USD million (2019-2032)
• Table 10: Berubicin Market Size in Spain, in USD million (2019-2032)
• Table 11: Berubicin Market Size in the UK, in USD million (2019-2032)
• Table 12: Berubicin Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Berubicin Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Berubicin Market Size in the United States, USD million (2019-2032)
• Figure 3: Berubicin Market Size in Germany, USD million (2019-2032)
• Figure 4: Berubicin Market Size in France, USD million (2019-2032)
• Figure 5: Berubicin Market Size in Italy, USD million (2019-2032)
• Figure 6: Berubicin Market Size in Spain, USD million (2019-2032)
• Figure 7: Berubicin Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Berubicin Market Size in Japan, USD million (2019-2032)

“"Berubicin Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about berubicin for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the berubicin for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the berubicin for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the berubicin market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary:

Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin treatment of brain cancer patients demonstrated positive responses, including one durable complete response in a Phase I human clinical trial conducted by Reata Pharmaceuticals. Berubicin is currently being evaluated in a global, potentially pivotal study.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the berubicin description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on berubicin regulatory milestones and other development activities have been provided in this report.
• The report also highlights the berubicin research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around berubicin.
• The report contains forecasted sales of berubicin for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for berubicin in GBM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Berubicin Analytical Perspective by DelveInsight

In-depth Berubicin Market Assessment

This report provides a detailed market assessment of berubicin for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

Berubicin Clinical Assessment

The report provides the clinical trials information of berubicin for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence berubicin dominance.
• Other emerging products for GBM are expected to give tough market competition to berubicin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of berubicin in GBM.
• Our in-depth analysis of the forecasted sales data of berubicin from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the berubicin in GBM.

Key Questions:

• What is the product type, route of administration and mechanism of action of berubicin?
• What is the clinical trial status of the study related to berubicin in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the berubicin development?
• What are the key designations that have been granted to berubicin for GBM?
• What is the forecasted market scenario of berubicin for GBM?
• What are the forecasted sales of berubicin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to berubicin for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?

Table of Contents

1. Report Introduction

2. Berubicin Overview in GBM

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Berubicin Market Assessment

• 5.1. Market Outlook of Berubicin in GBM
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Berubicin in the 7MM for GBM
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Berubicin in the United States for GBM
  • 5.3.2. Market Size of Berubicin in Germany for GBM
  • 5.3.3. Market Size of Berubicin in France for GBM
  • 5.3.4. Market Size of Berubicin in Italy for GBM
  • 5.3.5. Market Size of Berubicin in Spain for GBM
  • 5.3.6. Market Size of Berubicin in the United Kingdom for GBM
  • 5.3.7. Market Size of Berubicin in Japan for GBM

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options